Shuttle Pharmaceuticals Holdings (SHPH) Total Non-Current Liabilities (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Total Non-Current Liabilities of $8.4 million for Q1 2026, up 338.44% year-over-year from $1.9 million in Q1 2025, and up 3.91% quarter-over-quarter from $8.1 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $8.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 338.44% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 338.44% YoY), while the FY2025 annual figure was $8.1 million, up 358.38% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $8.4 million, up from $8.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $8.4 million in Q1 2026, with the low at $945765.0 in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $1.8 million (2024), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 49.83% in 2022, then soared 358.38% in 2025.
- Shuttle Pharmaceuticals Holdings' Total Non-Current Liabilities stood at $975676.0 in 2022, then jumped by 51.84% to $1.5 million in 2023, then climbed by 19.6% to $1.8 million in 2024, then jumped by 358.38% to $8.1 million in 2025, then rose by 3.91% to $8.4 million in 2026.
- Business Quant data shows SHPH's Total Non-Current Liabilities at $8.4 million in Q1 2026, $8.1 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Shuttle Pharmaceuticals Holdings | 1.87 Mn | 1.87 Mn | - | 8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.77 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 945,765.00 |
| Mar 31, 2023 | 2.14 Mn |
| Dec 31, 2022 | 975,676.00 |
| Sep 30, 2022 | 977,141.00 |
| Dec 31, 2021 | 1.94 Mn |